Lupin is currently trading at Rs. 916.00, up by 11.10 points or 1.23% from its previous closing of Rs. 904.90 on the BSE.
The scrip opened at Rs. 907.00 and has touched a high and low of Rs. 920.00 and Rs. 905.00 respectively. So far 70775 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1176.00 on 19-Jul-2017 and a 52 week low of Rs. 723.55 on 15-May-2018.
Last one week high and low of the scrip stood at Rs. 920.60 and Rs. 882.00 respectively. The current market cap of the company is Rs. 41342.12 crore.
The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 37.60% and 15.40% respectively.
Lupin is planning to launch around 30 generic products in the US market this year. The company has currently 162 abbreviated new drug applications pending approval with the US Food and Drug Administration (USFDA).
The company is banking on introduction of complex generics and biosimilars in the US, besides continuing focus on exclusive and semi-exclusive products in oral and injectable space to maintain its top five position in the market.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
